DIM-C-pPhCO2Me
- CAS No.
- 151358-48-4
- Chemical Name:
- DIM-C-pPhCO2Me
- Synonyms
- DIM-C-pPhCO2Me;DIM-C-pPhCO2Me >=98% (HPLC);DIM-C-pPhCO2Me, 10 mM in DMSO;Methyl 4-(di(1H-indol-3-yl)methyl)benzoate;Benzoic acid, 4-(di-1H-indol-3-ylmethyl)-, methyl ester;DIM-C-pPhCO2Me Methyl 4-[bis(1H-indol-3-yl)methyl]benzoate;DIMCpPhCO2Me,DIM-C-pPhCO-2Me,inhibit,Inhibitor,DIM C pPhCO2Me
- CBNumber:
- CB14718605
- Molecular Formula:
- C25H20N2O2
- Molecular Weight:
- 380.44
- MDL Number:
- MFCD31697720
- MOL File:
- 151358-48-4.mol
| Melting point | 98-100 °C |
|---|---|
| Boiling point | 618.6±50.0 °C(Predicted) |
| Density | 1.287±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C(protect from light) |
| solubility |
DMSO:100.5(Max Conc. mg/mL);264.16(Max Conc. mM) Ethanol:38.0(Max Conc. mg/mL);99.88(Max Conc. mM) |
| pka | 16.34±0.30(Predicted) |
| form | Solid |
| color | Light yellow to yellow |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| HS Code | 2933998090 |
DIM-C-pPhCO2Me price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biorbyt Ltd | orb573406 | DIM-C-pPhCO2Me >98% | 151358-48-4 | 100mg | $542.3 | 2021-12-16 | Buy |
| Biorbyt Ltd | orb573406 | DIM-C-pPhCO2Me >98% | 151358-48-4 | 250mg | $986 | 2021-12-16 | Buy |
| Biorbyt Ltd | orb573406 | DIM-C-pPhCO2Me >98% | 151358-48-4 | 1g | $2172.6 | 2021-12-16 | Buy |
| DC Chemicals | DC20223 | DIM-C-pPhCO2Me >98% | 151358-48-4 | 250mg | $650 | 2021-12-16 | Buy |
| Ambeed | A1145756 | DIM-C-pPhCO2Me 99+% | 151358-48-4 | 5mg | $75 | 2021-12-16 | Buy |
DIM-C-pPhCO2Me Chemical Properties,Uses,Production
Uses
DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research[1][2][3][4][5].
Biological Activity
DIM-C-pPhCO2Me is a NR4A1 (Nur77) antagonist th at exhibit potent anticancer activity in pancreatic, colon, breast, kidney, and rhabdomyosarcoma cells. DIM-C-pPhCO2Me decreases expression of PAX3-FOXO1A and β1-integrin proteins in Rh30 rhabdomyosarcoma and MDA-MB-231 breast cancer cells. DIM-C-pPhCO2Me inhibits migration of Rh30 and MDA-MB-231 cancer cells.', 'DIM-C-pPhCO2Me is also known as 1,1-bis(3μ-indolyl)-1-(p-carboxymethylphenyl)methane. In pancreatic and colon cancer cells, DIM-C-pPhCO2Me plays an inhibitory role on cell migration. DIM-C-pPhCO2Me prevents the action of mechanistic target of rapamycin (mTOR) and reduces the multiplication and survival of cancer cells. It stimulates reactive oxygen species (ROS) in various cancer cell lines.
in vivo
DIM-C-pPhCO2Me (2 mg/kg, single dose, intratracheally, 30 min before E. coliinfection) results in augmented phagocytic activity of AMs and reduces the mortality of mice with E. coli pneumonia[5].
| Animal Model: | Male mice with E. coli pneumonia[5] |
| Dosage: | 2 mg/kg, single dose |
| Administration: | intratracheally, 30 min before E. coli infection |
| Result: | Showed an obvious augmented phagocytic activity. Reduced the mortality in mice undergoing E. coli pneumonia (36.6% vs. 75%). |
IC 50
Nur77/NR4A1; IDH1
References
[1] Hedrick E, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015 Jun 2;10(6):e0128308. DOI:10.1371/journal.pone.0128308
[2] Hedrick E, et al. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocr Relat Cancer. 2015 Oct;22(5):831-40. DOI:10.1530/ERC-15-0063
[3] Lacey A, et al. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma. Mol Cancer Ther. 2018 Dec;17(12):2756-2766. DOI:10.1158/1535-7163.MCT-18-0118
[4] Lacey A, et al. PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1. Cancer Res. 2017 Feb 1;77(3):732-741. DOI:10.1158/0008-5472.CAN-16-1546
[5] Cui P, et al. Deficiency of the Transcription Factor NR4A1 Enhances Bacterial Clearance and Prevents Lung Injury During Escherichia Coli Pneumonia. Shock. 2019 Jun;51(6):787-794. DOI:10.1097/SHK.0000000000001184
DIM-C-pPhCO2Me Preparation Products And Raw materials
Raw materials
Preparation Products
DIM-C-pPhCO2Me Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32268 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38663 | 58 | |
| Shenyang Zhongshen Zekang Biomedical Technology Research Co., Ltd | +86-18341751992 +86-15382112998 | 757984502@qq.com | China | 892 | 58 |
| LEAPCHEM CO., LTD. | +86-852-30606658 | market18@leapchem.com | China | 43340 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| Shanghai Lollane Biological Technology Co.,Ltd. | 021-52996696，15000506266 15000506266 | China | 4611 | 55 | |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9803 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 71826 | 60 |
View Lastest Price from DIM-C-pPhCO2Me manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2025-04-28 | DIM-C-pPhCO2Me
151358-48-4
|
US $30.00-98.00 / mg | 99.86% | 10g | TargetMol Chemicals Inc. |
-
- DIM-C-pPhCO2Me
151358-48-4
- US $30.00-98.00 / mg
- 99.86%
- TargetMol Chemicals Inc.